A cost-focused comparison of brand-name Zepbound and compounded tirzepatide — self-pay tiers, retail, and where each makes sense.
Same molecule (tirzepatide), two regulatory categories. This page focuses on cost; for the full clinical and access comparison see our Zepbound vs compounded guide.
| Option | Type | From / month | FDA status |
|---|---|---|---|
| Compounded (NexLife, flat) | Compounded | $186/mo* | Not FDA-approved |
| Zepbound® LillyDirect self-pay | Brand | $299–$449/mo | FDA-approved |
| Zepbound® standard self-pay (window missed) | Brand | $599–$1,049/mo | FDA-approved |
| Zepbound® retail list | Brand | ~$1,086/mo | FDA-approved |
Compounded is generally the lowest cash cost; Zepbound is FDA-approved and may be insurance-covered. Verified July 2026.
On pure cash cost, flat-rate compounded ($186/mo) is typically lower than Zepbound self-pay ($299–$449/mo) and far below retail. But Zepbound is FDA-approved and may be covered by insurance, while compounded is not FDA-approved. Choose based on coverage, budget, and whether you want a branded product — a licensed clinician decides eligibility either way. See cost with insurance.
Usually yes on cash cost — flat compounded is about $186/month vs Zepbound self-pay $299–$449/month. But compounded is not FDA-approved, while Zepbound is and may be insurance-covered. See NexLife pricing
Both contain tirzepatide, but Zepbound is an FDA-approved Eli Lilly product and compounded tirzepatide is prepared by 503A/503B pharmacies and is not FDA-approved.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.